Get 30% off on all global market reports with code ONLINE30 – stay updated on tariff changes, macroeconomic trends, and more!
Empagliflozin, Dapagliflozin And Canagliflozin Industry Expansion: How the Market Size Has Grown Over the Last 5 Years?
The market for empagliflozin, dapagliflozin, and canagliflozin has been consistently expanding in the past few years. The market value is expected to rise from $9.64 billion in 2024 to approximately $9.84 billion in 2025, reflecting a compound annual growth rate (CAGR) of 2.1%.
The surge during the historic period can be ascribed to factors such as the escalating global prevalence of type 2 diabetes, enhanced understanding of the advantages of SGLT2 inhibitors, an upturn in the elderly population, an increase in obesity prevalence, and an intensified focus on personalized medicine.
In the coming years, the market size of empagliflozin, dapagliflozin and canagliflozin is set to witness constant expansion. By 2029, it is projected to reach $10.82 billion with a compound annual growth rate (CAGR) of 2.4%.
Factors that would contribute to growth during the forecast period include soaring demand for oral diabetes drugs, growth in investments for diabetes investigation and medication innovation, increased healthcare spending, heightened awareness and identification of pre-diabetic conditions, as well as a greater emphasis on combination treatments. During the forecast period, significant trends to look out for are technology progression, combined therapies, telehealth services, health data analytics, and safeguarding patient information.
Claim Your Free Sample Report:
http://www.thebusinessresearchcompany.com/sample….p;type=smp
What Core Factors Are Driving the Expansion of the Empagliflozin, Dapagliflozin And Canagliflozin Market?
The continued rise in diabetes cases worldwide is anticipated to stimulate the expansion of the empagliflozin, dapagliflozin, and canagliflozin market. The prominence of diabetes, a chronic condition characterized by elevated blood sugar levels due to insufficient insulin production or ineffective use, is on the rise due to factors such as inactive lifestyles, poor dietary patterns, genetic predisposition, urbanization, and an aging populace.
These factors are further exacerbated by limited healthcare access and growing global obesity statistics.
Empagliflozin, dapagliflozin, and canagliflozin are leveraged in diabetes control to reduce blood sugar by blocking sodium-glucose co-transporter-2 (SGLT2) in the kidneys and encouraging glucose expulsion via urination.
For instance, data from the National Health Service (NHS), a UK government agency, in June 2024 revealed an uptick in diabetes cases among those under 40, moving from 173,166 in 2022 to 216,440 in 2023. This notable increase indicates an alarming pattern in this demographic, demonstrating a swift surge in diabetes cases amongst young groups.
Hence, the rising prevalence of diabetes is fueling the growth of the empagliflozin, dapagliflozin, and canagliflozin market.
How Is the Empagliflozin, Dapagliflozin And Canagliflozin Market Structured Across Key Segments?
The empagliflozin, dapagliflozin and canagliflozinmarket covered in this report is segmented –
1) By Type: Empagliflozin; Dapagliflozin; Canagliflozin
2) By Application: Application I; Application II; Application III; Application IV
3) By Channel: Hospital; Pharmacy
Subsegments:
1) Empagliflozin: 10 Mg; 25 Mg; 50 Mg
2) Dapagliflozin: 5 Mg; 10 Mg
3) Canagliflozin: 100 Mg; 300 Mg
Access the Full Report Today:
http://www.thebusinessresearchcompany.com/report/…ket-report
What Innovation Trends Will Redefine the Empagliflozin, Dapagliflozin And Canagliflozin Market Landscape?
Leading businesses in the empagliflozin, dapagliflozin, and canagliflozin markets are concentrating on the creation of novel products, such as treatments for pediatric type-2 diabetes, as a strategy to cater to a larger patient groups and enhance their influence in diabetes management. Managing Type-2 diabetes in children involves lifestyle modifications, medication, and occasionally insulin therapy designed specifically for this age group.
UK-based pharmaceutical giant AstraZeneca, for instance, revealed in June 2024 that the US FDA had given their approval to their product Farxiga (dapagliflozin) aimed at improving blood sugar control among pediatric patients aged 10 and older diagnosed with type 2 diabetes. The approval was granted following encouraging results from the T2NOW Phase-III clinical trial, one of the most comprehensive studies on pediatric type-2 diabetes to date, which demonstrated that Farxiga significantly lowered HbA1c levels when compared to a placebo.
The safety record of Farxiga among these patients mirrored those found in adults suffering from type-2 diabetes. This approval represents a critical step forward, given the limited oral treatment alternatives for pediatric type-2 diabetes, and it reaffirms AstraZeneca’s dedication to introducing groundbreaking treatments in sectors such as cardiovascular, renal, and metabolic diseases.
Where Is the Empagliflozin, Dapagliflozin And Canagliflozin Market Experiencing the Fastest Regional Growth?
North America was the largest region in the empagliflozin, dapagliflozin and canagliflozin market in 2024. The regions covered in the empagliflozin, dapagliflozin and canagliflozin market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get a Customized Version of the Report:
http://www.thebusinessresearchcompany.com/customi…p;type=smp
Leading Players Shaping the Future of the Empagliflozin, Dapagliflozin And Canagliflozin Industry
Major companies operating in the empagliflozin, dapagliflozin and canagliflozin market are Pfizer Inc., Merck & Co. Inc., Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, GlaxoSmithKline plc, Eli Lilly and Company, Boehringer Ingelheim GmbH, Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., MSN Laboratories Private Limited, Dr.
Reddy’s Laboratories Ltd., Aurobindo Pharma Limited, Cipla Limited, Cadila Healthcare Limited, Apotex Inc., Lupin Limited, Biocon Limited, Alkem Laboratories Ltd., Torrent Pharmaceuticals Ltd., Alembic Pharmaceuticals Ltd., Intas Pharmaceuticals Ltd.
Access the Complete Report:
http://www.thebusinessresearchcompany.com/purchas…x?id=18350
How Our Market Research Reports Help Maximize ROI Across Industries:
* Identify High-Growth Opportunities: Pinpoint emerging trends, untapped segments, and regional hotspots that align with your strategic goals.
* Reduce Investment Risk: Make data-driven decisions with confidence by understanding market dynamics, key drivers, and competitive threats.
* Optimize Strategic Planning: Align your product development, marketing, and expansion plans with industry forecasts and customer behaviour insights.
Americas +1 310-496-7795
Europe +44 7882 955267
Asia & Others +44 7882 955267 & +91 8897263534
News From
The Business Research Company …
Category: Industry Reports & Market Analysis Profile: The Business Research Company is a leading market research and consulting services provider. It offers over 9,500 market reports across 27 industries in 60+ geographies, providing detailed insights and forecasts. Its customised research solutions support companies in making critical decisions, while its continuous research service enhances organizational capabilities. The flagship Global Market Model database provides comprehensive market intelligence with 1,500,000 datasets covering 8,000+ mark …
This email address is being protected from spambots. You need JavaScript enabled to view it.
